Interestingly, the de novo expression of EPHA2 in clinical osteosarcoma specimens and the proportional increase during progression from conventional to metastatic stages upgrades EPHA2 to a remarkable diagnostic biomarker. This evidence concerns the gene EPHA2 and osteosarcoma.